About Us

Vangenes Biotechnology Co., Ltd. is a high-tech enterprise integrating biotechnology research and development of high-performance medical supplies based in China.

Since 2013, VanGenes has applied next-generation DNA sequencing technology and bioanalysis technology to genetic testing in China.

After 9 years endeavor, VanGenes cancer early screening and tumor recurrence detection technologies are mature, with a detection rate of over 90%.

In addition, we have developed a cell-free DNA blood collection and preservation tube with independent intellectual property rights, which fills the blank space in Chinese market.

Nowadays , VanGenes has 4 R&D laboratories in Chinese cities, Xiamen, Shenzhen, Fuzhou, Pingtan and 1 R&D laboratory in Los Angeles, US.

The R&D team of VanGenes consists of experienced Ph.D.s and masters. We have 21 invention patents and 18 new utility technology patents, and have successively developed NIPT, NIPPT, mNGS, early cancer screening and leukemia gene fusion processes.

VanGenes Founder Dr. Chen Hongliang is awarded the honorary title of the  "Hundred Talents Program" leading entrepreneurial talents in Fujian province and the "Double Hundred Program" entrepreneurial talents in Xiamen city, China.